Zymeworks Inc.

NasdaqGS ZYME

Zymeworks Inc. EBITDA Margin for the year ending December 31, 2023: -158.79%

Zymeworks Inc. EBITDA Margin is -158.79% for the year ending December 31, 2023, a -544.85% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • Zymeworks Inc. EBITDA Margin for the year ending December 31, 2022 was 35.70%, a 104.62% change year over year.
  • Zymeworks Inc. EBITDA Margin for the year ending December 31, 2021 was -772.45%, a -69.82% change year over year.
  • Zymeworks Inc. EBITDA Margin for the year ending December 31, 2020 was -454.86%, a 6.15% change year over year.
  • Zymeworks Inc. EBITDA Margin for the year ending December 31, 2019 was -484.67%, a -735.54% change year over year.
Key data
Date EBITDA Margin EBIT Margin Depreciation and Amortization EBIT
Market news
SV Wall Street
NasdaqGS: ZYME

Zymeworks Inc.

CEO Mr. Kenneth H. Galbraith C.A.
IPO Date April 28, 2017
Location Canada
Headquarters 114 East 4th Avenue
Employees 294
Sector Healthcare
Industries
Biotechnology Clinical Trials Pharmaceuticals
Description

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.

Similar companies

SNDX

Syndax Pharmaceuticals, Inc.

USD 14.65

1.67%

INZY

Inozyme Pharma, Inc.

USD 1.52

11.77%

RVMD

Revolution Medicines, Inc.

USD 44.25

4.56%

EDIT

Editas Medicine, Inc.

USD 1.37

6.20%

TERN

Terns Pharmaceuticals, Inc.

USD 4.66

3.10%

RLAY

Relay Therapeutics, Inc.

USD 4.79

3.46%

AKRO

Akero Therapeutics, Inc.

USD 57.56

2.04%

PTGX

Protagonist Therapeutics, Inc.

USD 38.52

2.50%

ZNTL

Zentalis Pharmaceuticals, Inc.

USD 2.14

31.29%

ALEC

Alector, Inc.

USD 1.84

7.60%

ANNX

Annexon, Inc.

USD 3.70

0.27%

APLS

Apellis Pharmaceuticals, Inc.

USD 30.37

5.53%

DAWN

Day One Biopharmaceuticals, Inc.

USD 12.22

0.58%

CABA

Cabaletta Bio, Inc.

USD 2.44

5.17%

STOK

Stoke Therapeutics, Inc.

USD 12.70

0.79%

ARWR

Arrowhead Pharmaceuticals, Inc.

USD 20.27

3.00%

PRQR

ProQR Therapeutics N.V.

USD 2.12

-1.40%

TVTX

Travere Therapeutics, Inc.

USD 21.21

0.52%

CYTK

Cytokinetics, Incorporated

USD 50.41

2.46%

YMAB

Y-mAbs Therapeutics, Inc.

USD 6.21

3.50%

BLUE

bluebird bio, Inc.

USD 6.96

0.00%

BPMC

Blueprint Medicines Corporation

USD 110.37

-2.67%

StockViz Staff

February 7, 2025

Any question? Send us an email